EUVIMEDEUVIMED entdecken
Open Access

Reprogramming RIPK3-induced cell death in malignant B cells promotes immune-mediated tumor control

Ruby Alonso iD, Zacarias Garcia iD, Béatrice Corre, Fabrice Lemaître iD, Camille Vaganay iD, Hélène Saklani, Capucine L Grandjean iD, Nader Yatim iD, Philippe Bousso iD

Science Advances · 2025

DOI: 10.1126/sciadv.adv0871 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Ruby Alonso und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dynamics of Immune Responses Unit, Institut Pasteur, Université de Paris Cité, INSERM U1223, F-75015 Paris, France. Hauptthemen laut MEDLINE: Receptor-Interacting Protein Serine-Threonine Kinases, B-Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer therapies that induce immunogenic cell death such as necroptosis can arm the immune system to clear residual tumor cells. Receptor-interacting serine/threonine protein kinase 3 (RIPK3) signaling can trigger necroptosis, orchestrating immune responses to solid tumors. Whether RIPK3 activity can be exploited for controlling B cell malignancies remains unclear. Here, we establish a strategy to manipulate RIPK3 activity in malignant B cells and promote immune-mediated tumor control. By controlling and visualizing RIPK3 signaling using intravital imaging, we established that RIPK3 activation promoted apoptosis and rapid macrophage engulfment but failed to induce necroptosis due to limited MLKL expression in B-lineage cells. RIPK3-induced cell death could be diverted toward necroptosis with type I IFN and caspase inhibition. Exploiting these findings, we showed that a combination therapy activating RIPK3 with SMAC mimetics while suppressing caspase activity and providing type I IFN resulted in immune-mediated control of B cell tumors. Hence, reprogramming RIPK3 activity represents an attractive therapeutic opportunity to target B cell malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor-Interacting Protein Serine-Threonine KinasesB-LymphocytesAnimalsMiceHumansNecroptosisSignal TransductionApoptosisCell Line, TumorInterferon Type ICell DeathMacrophagesMice, Inbred C57BL

Substanzen

Receptor-Interacting Protein Serine-Threonine KinasesRIPK3 protein, humanRipk3 protein, mouseInterferon Type I

Autor:innen und Institutionen

  • Dynamics of Immune Responses Unit, Institut Pasteur, Université de Paris Cité, INSERM U1223, F-75015 Paris, France.
  • Translational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.

ORCID-Profile: Ruby Alonso, Zacarias Garcia, Fabrice Lemaître, Camille Vaganay, Capucine L Grandjean, Nader Yatim, Philippe Bousso

Zitieren

APA

Alonso, R., Garcia, Z., Corre, B., Lemaître, F., Vaganay, C., Saklani, H., Grandjean, C. L., Yatim, N., & Bousso, P. (2025). Reprogramming RIPK3-induced cell death in malignant B cells promotes immune-mediated tumor control. Science Advances. https://doi.org/10.1126/sciadv.adv0871

Vancouver

Alonso R, Garcia Z, Corre B, Lemaître F, Vaganay C, Saklani H, et al. Reprogramming RIPK3-induced cell death in malignant B cells promotes immune-mediated tumor control. Science Advances. 2025. doi:10.1126/sciadv.adv0871

BibTeX
@article{Alonso2025,
  author = {Alonso, Ruby and Garcia, Zacarias and Corre, Béatrice and Lemaître, Fabrice and Vaganay, Camille and Saklani, Hélène and Grandjean, Capucine L and Yatim, Nader and Bousso, Philippe},
  title = {Reprogramming RIPK3-induced cell death in malignant B cells promotes immune-mediated tumor control},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.adv0871}
}
Kostenlos starten →